The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin

British Journal of Dermatology

Volumn 139, Issue 3, 1998, Pages 380-389

  Kuijpers, A L A ^a   Van Pelt, J P A ^a   Bergers, M ^a   Boegheim, P J ^b   Den Bakker, J E N ^a   Siegenthaler, G ^c   Van De Kerkhof, P C M ^a   Schalkwijk, J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Clinical Research ^*  (Netherlands)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 INHIBITOR; CYTOKERATIN; ETRETIN; FATTY ACID BINDING PROTEIN; KI 67 ANTIGEN; LIAROZOLE; RETINOIC ACID;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPIDERMIS CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; RANDOMIZED CONTROLLED TRIAL;

ACITRETIN; ADMINISTRATION, ORAL; ADULT; AGED; CELL DIFFERENTIATION; CELL DIVISION; DOUBLE-BLIND METHOD; EPIDERMIS; FEMALE; HUMANS; IMIDAZOLES; IMMUNOENZYME TECHNIQUES; KERATOLYTIC AGENTS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; PSORIASIS; SERINE PROTEINASE INHIBITORS;

EID: 0031713597     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02399.x     Document Type: Article

References (32)

1. Van Wauwe JP, Coene MC, Goossens J et al. Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 1990; 252: 365-9.
2. Van Wauwe J, Van Nyen G, Coene MC et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 1992; 261: 773-9.
3. Kang S, Duell EA, Kim KJ, Voorhees JJ. Liarozole inhibits human epidermal retinoic acid 4-hydroxylase activity and differentially augments human skin responses to retinoic acid and retinol in vivo. J Invest Dermatol 1996; 107: 183-7.
4. Dockx P, Decree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol 1995; 133: 426-32.
5. Pilkington T, Brogden RN. Acitretin. A review of its pharmacology and therapeutic use. Drugs 1992; 43: 597-627.
6. Fritsch PO. Retinoids in psoriasis and disorders of keratinization. J Am Acad Dermatol 1992; 27: S8-14.
7. Lucker GP, Heremans AM, Boegheim PJ et al. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol 1997; 136: 71-5.
8. Ponec M. Retinoid-induced modulation of differentiation, keratin and lipid composition in reconstructed epidermis in vitro. In: Pharmacology of Retinoids in the Skin (Reichert U, Shroot B, eds). Basel: Karger, 1989; 45-51.
9. Elder JT, Kaplan A, Cromie MA et al. Retinoid induction of CRABP II mRNA in human dermal fibroblasts: use as a retinoid bioassay. J Invest Dermatol 1996; 106: 517-21.
10. Molhuizen HOF, Alkemade HAC, Zeeuwen PLJM et al. SKALP/ elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem 1993; 268: 12028-32.
11. Siegenthaler G, Hotz R, Chatellard Gruaz D et al. Purification and characterization of the human epidermal fatty acid-binding protein: localization during epidermal cell differentiation in vivo and in vitro. Biochem J 1994; 302: 363-71.
12. Kuijpers ALA, Bergers AM, Siegenthaler G et al. Skin-derived antileukoproteinase (SKALP) and epidermal fatty acid-binding protein (E-FABP): two novel markers of the psoriatic phenotype that respond differentially to topical steroid. Acta Derm Venereol (Stockh) 1997; 77: 14-19.
13. Le M, Schalkwijk J, van Siegenthaler G, de Kerkhof PCM. Changes in keratinocyte differentiation following mild irritation by sodium dodecyl sulphate. Arch Dermatol Res 1996; 288: 684-90.
14. Van Muijen GNP, Ruiter DJ, Franke WW et al. Cell type heterogeneity of cytokeratin expression in complex epithelia and carcinomas as demonstrated by monoclonal antibodies specific for cytokeratins nos 4 and 13. Exp Cell Res 1986; 162: 97-113.
15. Schalkwijk J, van Vlijmen-Willems IMJJ, Alkemade JAC, de Jongh GJ. Immunohistochemical localization of SKALP/elafin in psoriatic epidermis. J Invest Dermatol 1993; 100: 390-3.
16. Steel RGD, Torrie JH. Principles and Procedures of Statistics: a Biometrical Approach, 2nd edn. Tokyo: McGraw-Hill Kogakusha, 1980; 280-2.
17. van Erp PE, de Mare S, Rijzewijk JJ et al. A sequential double immunoenzymic staining procedure to obtain cell kinetic information in normal and hyperproliferative epidermis. Histochem J 1989; 21: 343-7.
18. Rijzewijk JJ, van Erp PEJ, Bauer FW. Two binding sites for Ki-67 related to quiescent and cycling cells in human epidermis. Acta Derm Venereol (Stockh) 1989; 69: 512-15.
19. de Mare S, van Erp PEJ, de Kerkhof PCM. Epidermal hyperproliferation assessed by the monoclonal antibody Ks8.12 on frozen sections. J Invest Dermatol 1989; 92: 130-1.
20. Michel S, Demarchez M. Localization and in vivo activity of epidermal transglutaminase. J Invest Dermatol 1988; 90: 472-4.
21. Nonomura K, Yamanishi K, Hosokawa Y et al. Localization of transglutaminase 1 mRNA in normal and psoriatic epidermis by non-radioactive in situ hybridization. Br J Dermatol 1993; 128: 23-8.
22. Zeeuwen PLJM, Hendriks W, de Jong WW, Schalkwijk J. Identification and sequence analysis of two new members of the SKALP/ elafin and SPA1-2 gene family. Biochemical properties of the transglutaminase substrate motif and suggestions for a new nomenclature. J Biol Chem 1997; 272: 20471-8.
23. Alkemade HAC, de Jongh GJ, Arnold WP et al. Levels of skin-derived antileukoproteinase (SKALP)/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporin A. J Invest Dermatol 1995; 104: 189-93.
24. Masouye I, Saurat JH, Siegenthaler G. Epidermal fatty-acid-binding protein in psoriasis, basal and squamous cell carcinomas: an immunohistological study. Dermatology 1996; 192: 208-13.
25. Van Muijen GN, Warnaar SO, Ponec M. Differentiation-related changes of cytokeratin expression in cultured keratinocytes and in fetal, newborn, and adult epidermis. Exp Cell Res 1987; 171: 331-45.
26. de Jong EMGJ, Ferrier CM, de Zwart A et al. Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci 1995; 9: 185-94.
27. de Jong EMGJ, de Kerkhof PCM. Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: modulations and interrelations. Br J Dermatol 1991; 124: 221-9.
28. van der Vleuten CJ, de Jong EMGJ, de Kerkhof PCM. Epidermal differentiation characteristics of the psoriatic plaque during treatment with calcipotriol. Arch Dermatol Res 1996; 288: 366-72.
29. van der Vleuten CJ, de Jong EMGJ, de Kerkhof PCM. Epidermal differentiation characteristics of the psoriatic plaque during short contact treatment with dithranol cream. Clin Exp Dermatol 1996; 21: 409-14.
30. Swanbeck G, Liden S. The inhibitory effect of dithranol (anthralin) on DNA synthesis. Acta Derm Venereol (Stockh) 1966; 46: 228-30.
31. Thacher SM, Rice RH. Keratinocyte-specific transglutaminase of cultured human epidermal cells: relation to cross-linked envelope formation and terminal differentiation. Cell 1985; 40: 685-95.
32. Buxman MM, Wuepper KD. Keratin cross-linking and epidermal transglutaminase. A review with observations on the histochemical and immunochemical localization of the enzyme. J Invest Dermatol 1975; 65: 107-12.